PRADAXA 75mg Hard capsule Ref.[7222] Active ingredients: Dabigatran

Source: European Medicines Agency (EU)  Revision Year: 2022  Publisher: Boehringer Ingelheim International GmbH, Binger Str. 173, 55216 Ingelheim am Rhein, Germany

Contraindications

  • Hypersensitivity to the active substance or to any of the excipients listed in section 6.1
  • Severe renal impairment (CrCL <30 mL/min) in adult patients
  • eGFR <50 mL/min/1.73m² in paediatric patients
  • Active clinically significant bleeding
  • Lesion or condition, if considered a significant risk factor for major bleeding. This may include current or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities
  • Concomitant treatment with any other anticoagulants e.g. unfractionated heparin (UFH), low molecular weight heparins (enoxaparin, dalteparin etc), heparin derivatives (fondaparinux etc), oral anticoagulants (warfarin, rivaroxaban, apixaban etc) except under specific circumstances. These are switching anticoagulant therapy (see section 4.2), when UFH is given at doses necessary to maintain an open central venous or arterial catheter or when UFH is given during catheter ablation for atrial fibrillation (see section 4.5)
  • Hepatic impairment or liver disease expected to have any impact on survival
  • Concomitant treatment with the following strong P-gp inhibitors: systemic ketoconazole, cyclosporine, itraconazole, dronedarone and the fixed-dose combination glecaprevir/pibrentasvir (see section 4.5)
  • Prosthetic heart valves requiring anticoagulant treatment (see section 5.1).

Special warnings and precautions for use

Haemorrhagic risk

Dabigatran etexilate should be used with caution in conditions with an increased risk of bleeding or with concomitant use of medicinal products affecting haemostasis by inhibition of platelet aggregation. Bleeding can occur at any site during therapy. An unexplained fall in haemoglobin and/or haematocrit or blood pressure should lead to a search for a bleeding site.

For adult patients in situations of life-threatening or uncontrolled bleeding, when rapid reversal of the anticoagulation effect of dabigatran is required, the specific reversal agent idarucizumab is available. The efficacy and safety of idarucizumab have not been established in paediatric patients. Haemodialysis can remove dabigatran. For adult patients, fresh whole blood or fresh frozen plasma, coagulation factor concentration (activated or non-activated), recombinant factor VIIa or platelet concentrates are other possible options (see also section 4.9).

Use of platelet aggregation inhibitors such as clopidogrel and acetylsalicylic acid (ASA) or non steroidal antiinflammatory drugs (NSAID), as well as the presence of esophagitis, gastritis or gastroesophageal reflux increase the risk of GI bleeding.

Risk factors

Table 3 summarises factors which may increase the haemorrhagic risk.

Table 3. Factors which may increase the haemorrhagic risk:

 Risk factor
Pharmacodynamic and kinetic factors Age ≥75 years
Factors increasing dabigatran plasma levels Major:
• Moderate renal impairment in adult
patients (30-50 mL/min CrCL)
• Strong P-gp inhibitors (see section 4.3 and
4.5)
• Mild to moderate P-gp inhibitor
co-medication (e.g. amiodarone, verapamil,
quinidine and ticagrelor; see section 4.5)

Minor:
• Low body weight (<50 kg) in adult patients
Pharmacodynamic interactions (see section 4.5) • ASA and other platelet aggregation
inhibitors such as clopidogrel
• NSAIDs
• SSRIs or SNRIs
• Other medicinal products which may
impair haemostasis
Diseases / procedures with special
haemorrhagic risks
• Congenital or acquired coagulation
disorders
• Thrombocytopenia or functional platelet

Limited data is available in patients <50 kg (see section 5.2).

The concomitant use of dabigatran etexilate with P-gp-inhibitors has not been studied in paediatric patients but may increase the risk of bleeding (see section 4.5).

Precautions and management of the haemorrhagic risk

For the management of bleeding complications, see also section 4.9.

Benefit-risk assessment:

The presence of lesions, conditions, procedures and/or pharmacological treatment (such as NSAIDs, antiplatelets, SSRIs and SNRIs, see section 4.5), which significantly increase the risk of major bleeding requires a careful benefit-risk assessment. Dabigatran etexilate should only be given if the benefit outweighs bleeding risks.

Limited clinical data are available for paediatric patients with risk factors, including patients with active meningitis, encephalitis and intracranial abscess (see section 5.1). In these patients, dabigatran etexilate should only be given if the expected benefit outweighs bleeding risks.

Close clinical surveillance:

Close observation for signs of bleeding or anaemia is recommended throughout the treatment period, especially if risk factors are combined (see table 3 above). Particular caution should be exercised when dabigatran etexilate is co-administered with verapamil, amiodarone, quinidine or clarithromycin (P-gp inhibitors) and particularly in the occurrence of bleeding, notably in patients having a reduced renal function (see section 4.5).

Close observation for signs of bleeding is recommended in patients concomitantly treated with NSAIDs (see section 4.5).

Discontinuation of dabigatran etexilate:

Patients who develop acute renal failure must discontinue dabigatran etexilate (see also section 4.3).

When severe bleedings occur, treatment must be discontinued, the source of bleeding investigated and use of the specific reversal agent (idarucizumab) may be considered in adult patients. The efficacy and safety of idarucizumab have not been established in paediatric patients. Haemodialysis can remove dabigatran.

Use of proton-pump inhibitors:

The administration of a proton-pump inhibitor (PPI) can be considered to prevent GI bleeding. In case of paediatric patients local labeling recommendations for proton pump inhibitors have to be followed.

Laboratory coagulation parameters:

Although this medicinal product does not in general require routine anticoagulant monitoring, the measurement of dabigatran related anticoagulation may be helpful to detect excessive high exposure to dabigatran in the presence of additional risk factors.

Diluted thrombin time (dTT), ecarin clotting time (ECT) and activated partial thromboplastin time (aPTT) may provide useful information, but results should be interpreted with caution due to inter-test variability (see section 5.1).

The international normalised ratio (INR) test is unreliable in patients on dabigatran etexilate and false positive INR elevations have been reported. Therefore INR tests should not be performed.

Table 4 shows coagulation test thresholds at trough for adult patients that may be associated with an increased risk of bleeding. Respective thresholds for paediatric patients are not known (see section 5.1).

Table 4. Coagulation test thresholds at trough that may be associated with an increased risk of bleeding:

Test (trough value)  
dTT [ng/mL] >67
ECT [x-fold upper limit of normal] No data
aPTT [x-fold upper limit of normal] >1.3
INRShould not be performed

Use of fibrinolytic medicinal products for the treatment of acute ischemic stroke

The use of fibrinolytic medicinal products for the treatment of acute ischemic stroke may be considered if the patient presents with a dTT, ECT or aPTT not exceeding the upper limit of normal (ULN) according to the local reference range.

Surgery and interventions

Patients on dabigatran etexilate who undergo surgery or invasive procedures are at increased risk for bleeding. Therefore, surgical interventions may require the temporary discontinuation of dabigatran etexilate.

Caution should be exercised when treatment is temporarily discontinued for interventions and anticoagulant monitoring is warranted. Clearance of dabigatran in patients with renal insufficiency may take longer (see section 5.2). This should be considered in advance of any procedures. In such cases a coagulation test (see sections 4.4 and 5.1) may help to determine whether haemostasis is still impaired.

Emergency surgery or urgent procedures

Dabigatran etexilate should be temporarily discontinued. When rapid reversal of the anticoagulation effect is required the specific reversal agent (idarucizumab) to dabigatran is available for adult patients. The efficacy and safety of idarucizumab have not been established in paediatric patients. Haemodialysis can remove dabigatran.

Reversing dabigatran therapy exposes patients to the thrombotic risk of their underlying disease. Dabigatran etexilate treatment can be re-initiated 24 hours after administration of idarucizumab, if the patient is clinically stable and adequate haemostasis has been achieved.

Subacute surgery/interventions

Dabigatran etexilate should be temporarily discontinued. A surgery / intervention should be delayed if possible until at least 12 hours after the last dose. If surgery cannot be delayed the risk of bleeding may be increased. This risk of bleeding should be weighed against the urgency of intervention.

Elective surgery

If possible, dabigatran etexilate should be discontinued at least 24 hours before invasive or surgical procedures. In patients at higher risk of bleeding or in major surgery where complete haemostasis may be required consider stopping dabigatran etexilate 2-4 days before surgery.

Table 5 summarises discontinuation rules before invasive or surgical procedures for adult patients.

Table 5. Discontinuation rules before invasive or surgical procedures:

Renal function
(CrCL in
mL/min)
Estimated half-life
(hours)
Dabigatran etexilate should be stopped before elective
surgery
High risk of bleeding or
major surgery
Standard risk
≥80~132 days before24 hours before
≥50-<80~152-3 days before1-2 days before
≥30-<50~184 days before2-3 days before (>48 hours)

Discontinuation rules before invasive or surgical procedures for paediatric patients are summarised in table 6.

Table 6. Discontinuation rules before invasive or surgical procedures for paediatric patients:

Renal function
(eGFR in mL/min/1.73m²)
Stop dabigatran before elective surgery
>80 24 hours before
50 – 80 2 days before
<50 These patients have not been studied (see section 4.3).

Spinal anaesthesia/epidural anaesthesia/lumbar puncture

Procedures such as spinal anaesthesia may require complete haemostatic function.

The risk of spinal or epidural haematoma may be increased in cases of traumatic or repeated puncture and by the prolonged use of epidural catheters. After removal of a catheter, an interval of at least 2 hours should elapse before the administration of the first dose of dabigatran etexilate. These patients require frequent observation for neurological signs and symptoms of spinal or epidural haematoma.

Postoperative phase

Dabigatran etexilate should be restarted after the invasive procedure or surgical intervention as soon as possible provided the clinical situation allows and adequate haemostasis has been established.

Patients at risk for bleeding or patients at risk of overexposure, notably patients with reduced renal function (see also table 3), should be treated with caution (see sections 4.4 and 5.1).

Patients at high surgical mortality risk and with intrinsic risk factors for thromboembolic events

There are limited efficacy and safety data for dabigatran etexilate available in these patients and therefore they should be treated with caution.

Hip fracture surgery

There is no data on the use of dabigatran etexilate in patients undergoing hip fracture surgery. Therefore treatment is not recommended.

Hepatic impairment

Patients with elevated liver enzymes >2 ULN were excluded in the main trials. No treatment experience is available for this subpopulation of patients, and therefore the use of dabigatran etexilate is not recommended in this population. Hepatic impairment or liver disease expected to have any impact on survival is contraindicated (see section 4.3).

Interaction with P-gp inducers

Concomitant administration of P-gp inducers is expected to result in decreased dabigatran plasma concentrations, and should be avoided (see sections 4.5 and 5.2).

Patients with antiphospholipid syndrome

Direct acting Oral Anticoagulants (DOACs) including dabigatran etexilate are not recommended for patients with a history of thrombosis who are diagnosed with antiphospholipid syndrome. In particular for patients that are triple positive (for lupus anticoagulant, anticardiolipin antibodies, and anti–beta 2-glycoprotein I antibodies), treatment with DOACs could be associated with increased rates of recurrent thrombotic events compared with vitamin K antagonist therapy.

Active cancer patients (paediatric VTE)

There is limited data on efficacy and safety for paediatric patients with active cancer.

Paediatric population

For some very specific paediatric patients, e.g. patients with small bowel disease where absorption may be affected, use of an anticoagulant with parenteral route of administration should be considered.

Interaction with other medicinal products and other forms of interaction

Transporter interactions

Dabigatran etexilate is a substrate for the efflux transporter P-gp. Concomitant administration of P-gp inhibitors (see table 7) is expected to result in increased dabigatran plasma concentrations.

If not otherwise specifically described, close clinical surveillance (looking for signs of bleeding or anaemia) is required when dabigatran is co-administered with strong P-gp inhibitors. Dose reductions may be required in combination with some P-gp inhibitors (see sections 4.2, 4.3, 4.4 and 5.1).

Table 7. Transporter interactions:

P-gp inhibitors
Concomitant use contraindicated (see section 4.3)
Ketoconazole Ketoconazole increased total dabigatran AUC0-∞ and Cmax values by 2.38-fold and
2.35-fold, respectively, after a single oral dose of 400 mg, and by 2.53-fold and
2.49-fold, respectively, after multiple oral dosing of 400 mg ketoconazole once
daily.
Dronedarone When dabigatran etexilate and dronedarone were given at the same time total
dabigatran AUC0-∞ and Cmax values increased by about 2.4-fold and 2.3-fold,
respectively, after multiple dosing of 400 mg dronedarone bid, and about 2.1-fold
and 1.9-fold, respectively, after a single dose of 400 mg.
Itraconazole,
cyclosporine
Based on in vitro results a similar effect as with ketoconazole may be expected.
Glecaprevir /
pibrentasvir
The concomitant use of dabigatran etexilate with the fixed-dose combination of the
P-gp inhibitors glecaprevir/pibrentasvir has been shown to increase exposure of
dabigatran and may increase the risk of bleeding.
Concomitant use not recommended
Tacrolimus Tacrolimus has been found in vitro to have a similar level of inhibitory effect on
P-gp as that seen with itraconazole and cyclosporine. Dabigatran etexilate has not been
clinically studied together with tacrolimus. However, limited clinical data with
another P-gp substrate (everolimus) suggest that the inhibition of P-gp with
tacrolimus is weaker than that observed with strong P-gp inhibitors.
Cautions to be exercised in case concomitant use (see sections 4.2 and 4.4)
Verapamil When dabigatran etexilate (150 mg) was co-administered with oral verapamil, the
Cmax and AUC of dabigatran were increased but the magnitude of this change
differs depending on timing of administration and formulation of verapamil (see
sections 4.2 and 4.4).

The greatest elevation of dabigatran exposure was observed with the first dose of an
immediate release formulation of verapamil administered one hour prior to the
dabigatran etexilate intake (increase of Cmax by about 2.8-fold and AUC by about
2.5-fold). The effect was progressively decreased with administration of an
extended release formulation (increase of Cmax by about 1.9-fold and AUC by about
1.7-fold) or administration of multiple doses of verapamil (increase of Cmax by
about 1.6-fold and AUC by about 1.5-fold).

There was no meaningful interaction observed when verapamil was given 2 hours
after dabigatran etexilate (increase of Cmax by about 1.1-fold and AUC by about
1.2-fold). This is explained by completed dabigatran absorption after 2 hours.
Amiodarone When dabigatran etexilate was co-administered with a single oral dose of 600 mg
amiodarone, the extent and rate of absorption of amiodarone and its active
metabolite DEA were essentially unchanged. The dabigatran AUC and Cmax were
increased by about 1.6-fold and 1.5-fold, respectively. In view of the long half-life
of amiodarone the potential for an interaction may exist for weeks after
discontinuation of amiodarone (see sections 4.2 and 4.4).
Quinidine Quinidine was given as 200 mg dose every 2nd hour up to a total dose of 1,000 mg.
Dabigatran etexilate was given twice daily over 3 consecutive days, on the 3rd day
either with or without quinidine. Dabigatran AUCτ,ss and Cmax,ss were increased on
average by 1.53-fold and 1.56-fold, respectively with concomitant quinidine (see
sections 4.2 and 4.4).
Clarithromycin When clarithromycin (500 mg twice daily) was administered together with
dabigatran etexilate in healthy volunteers, increase of AUC by about 1.19-fold and
Cmax by about 1.15-fold was observed.
Ticagrelor When a single dose of 75 mg dabigatran etexilate was coadministered
simultaneously with a loading dose of 180 mg ticagrelor, the dabigatran AUC and
Cmax were increased by 1.73-fold and 1.95-fold, respectively. After multiple doses
of ticagrelor 90 mg b.i.d. the increase of dabigatran exposure is 1.56-fold and
1.46-fold for Cmax and AUC, respectively.

Concomitant administration of a loading dose of 180 mg ticagrelor and 110 mg
dabigatran etexilate (in steady state) increased the dabigatran AUCτ,ss and Cmax,ss by
1.49-fold and 1.65-fold, respectively, compared with dabigatran etexilate given
alone. When a loading dose of 180 mg ticagrelor was given 2 hours after 110 mg
dabigatran etexilate (in steady state), the increase of dabigatran AUCτ,ss and Cmax,ss
was reduced to 1.27-fold and 1.23-fold, respectively, compared with dabigatran
etexilate given alone. This staggered intake is the recommended administration for
start of ticagrelor with a loading dose.

Concomitant administration of 90 mg ticagrelor b.i.d. (maintenance dose) with<br /110 mg dabigatran etexilate increased the adjusted dabigatran AUCτ,ss and Cmax,ss
1.26-fold and 1.29-fold, respectively, compared with dabigatran etexilate given
alone.
Posaconazole Posaconazole also inhibits P-gp to some extent but has not been clinically studied.
Caution should be exercised when dabigatran etexilate is co-administered with
posaconazole.
P-gp inducers
Concomitant use should be avoided.
e.g. rifampicin,
St. John´s wort
(Hypericum
perforatum),
carbamazepine,
or phenytoin
Concomitant administration is expected to result in decreased dabigatran
concentrations.

Pre-dosing of the probe inducer rifampicin at a dose of 600 mg once daily for
7 days decreased total dabigatran peak and total exposure by 65.5% and 67%,
respectively. The inducing effect was diminished resulting in dabigatran exposure
close to the reference by day 7 after cessation of rifampicin treatment. No further
increase in bioavailability was observed after another 7 days.
Protease inhibitors such as ritonavir
Concomitant use not recommended
e.g. ritonavir
and its
combinations
with other
protease
inhibitors
These affect P-gp (either as inhibitor or as inducer). They have not been studied and
are therefore not recommended for concomitant treatment with dabigatran etexilate.
P-gp substrate
Digoxin In a study performed with 24 healthy subjects, when dabigatran etexilate was
co-administered with digoxin, no changes on digoxin and no clinically relevant
changes on dabigatran exposure have been observed.

Anticoagulants and antiplatelet aggregation medicinal products

There is no or only limited experience with the following treatments which may increase the risk of bleeding when used concomitantly with dabigatran etexilate: anticoagulants such as unfractionated heparin (UFH), low molecular weight heparins (LMWH), and heparin derivatives (fondaparinux, desirudin), thrombolytic medicinal products, and vitamin K antagonists, rivaroxaban or other oral anticoagulants (see section 4.3), and antiplatelet aggregation medicinal products such as GPIIb/IIIa receptor antagonists, ticlopidine, prasugrel, ticagrelor, dextran, and sulfinpyrazone (see section 4.4). UFH can be administered at doses necessary to maintain a patent central venous or arterial catheter or during catheter ablation for atrial fibrillation (see section 4.3).

Table 8. Interactions with anticoagulants and antiplatelet aggregation medicinal products:

NSAIDs NSAIDs given for short-term analgesia have been shown not to be associated with
increased bleeding risk when given in conjunction with dabigatran etexilate. With
chronic use in a phase III clinical trial comparing dabigatran to warfarin for stroke
prevention in atrial fibrillation patients (RE-LY), NSAIDs increased the risk of bleeding
by approximately 50% on both dabigatran etexilate and warfarin.
Clopidogrel In young healthy male volunteers, the concomitant administration of dabigatran
etexilate and clopidogrel resulted in no further prolongation of capillary bleeding times
compared to clopidogrel monotherapy. In addition, dabigatran AUCτ,ss and Cmax,ss and
the coagulation measures for dabigatran effect or the inhibition of platelet aggregation
as measure of clopidogrel effect remained essentially unchanged comparing combined
treatment and the respective mono-treatments. With a loading dose of 300 mg or
600 mg clopidogrel, dabigatran AUCτ,ss and Cmax,ss were increased by about 30-40%
(see section 4.4).
ASA Co-administration of ASA and 150 mg dabigatran etexilate twice daily may increase the
risk for any bleeding from 12% to 18% and 24% with 81 mg and 325 mg ASA,
respectively (see section 4.4).
LMWH The concomitant use of LMWHs, such as enoxaparin and dabigatran etexilate has not
been specifically investigated. After switching from 3-day treatment of once daily
40 mg enoxaparin s.c., 24 hours after the last dose of enoxaparin the exposure to
dabigatran was slightly lower than that after administration of dabigatran etexilate
(single dose of 220 mg) alone. A higher anti-FXa/FIIa activity was observed after
dabigatran etexilate administration with enoxaparin pre-treatment compared to that after
treatment with dabigatran etexilate alone. This is considered to be due to the carry-over
effect of enoxaparin treatment, and regarded as not clinically relevant. Other dabigatran
related anti-coagulation tests were not changed significantly by the pre-treatment of
enoxaparin.

Other interactions

Table 9. Other interactions:

Selective serotonin re-uptake inhibitors (SSRIs) or selective serotonin norepinephrine re-uptake
inhibitors (SNRIs)
SSRIs, SNRIs SSRIs and SNRIs increased the risk of bleeding in all treatment groups of a phase III
clinical trial comparing dabigatran to warfarin for stroke prevention in atrial
fibrillation patients (RE-LY).
Substances influencing gastric pH
Pantoprazole When Pradaxa was co-administered with pantoprazole, a decrease in the dabigatran
AUC of approximately 30% was observed. Pantoprazole and other proton-pump
inhibitors (PPI) were co-administered with Pradaxa in clinical trials, and concomitant
PPI treatment did not appear to reduce the efficacy of Pradaxa.
Ranitidine Ranitidine administration together with dabigatran etexilate had no clinically
relevant effect on the extent of absorption of dabigatran.

Interactions linked to dabigatran etexilate and dabigatran metabolic profile

Dabigatran etexilate and dabigatran are not metabolised by the cytochrome P450 system and have no in vitro effects on human cytochrome P450 enzymes. Therefore, related medicinal product interactions are not expected with dabigatran.

Paediatric population

Interaction studies have only been performed in adults.

Fertility, pregnancy and lactation

Women of childbearing potential

Women of childbearing potential should avoid pregnancy during treatment with Pradaxa.

Pregnancy

There is limited amount of data from the use of Pradaxa in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown.

Pradaxa should not be used during pregnancy unless clearly necessary.

Breast-feeding

There are no clinical data of the effect of dabigatran on infants during breast-feeding. Breast-feeding should be discontinued during treatment with Pradaxa.

Fertility

No human data available.

In animal studies an effect on female fertility was observed in the form of a decrease in implantations and an increase in pre-implantation loss at 70 mg/kg (representing a 5-fold higher plasma exposure level compared to patients). No other effects on female fertility were observed. There was no influence on male fertility. At doses that were toxic to the mothers (representing a 5- to 10-fold higher plasma exposure level to patients), a decrease in foetal body weight and embryofoetal viability along with an increase in foetal variations were observed in rats and rabbits. In the pre- and post-natal study, an increase in foetal mortality was observed at doses that were toxic to the dams (a dose corresponding to a plasma exposure level 4-fold higher than observed in patients).

Effects on ability to drive and use machines

Dabigatran etexilate has no or negligible influence on the ability to drive and use machines.

Undesirable effects

Summary of the safety profile

Dabigatran etexilate has been evaluated in clinical trials overall in approximately 64,000 patients; there of approximately 35,000 patients were treated with dabigatran etexilate.

In actively controlled VTE prevention trials 6,684 patients were treated with 150 mg or 220 mg dabigatran etexilate daily.

The most commonly reported events are bleedings occurring in approximately 14 % of patients; the frequency of major bleeds (including wound site bleedings) is less than 2 %.

Although rare in frequency in clinical trials, major or severe bleeding may occur and, regardless of location, may lead to disabling, life-threatening or even fatal outcomes.

Tabulated list of adverse reactions

Table 10 shows the adverse reactions ranked under headings of System Organ Classes (SOC) and frequency using the following convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).

Table 10. Adverse reactions:

SOC / Preferred term Frequency
Blood and lymphatic system disorders
Haemoglobin decreased Common
Anaemia Uncommon
Haematocrit decreased Uncommon
Thrombocytopenia Rare
NeutropeniaNot known
AgranulocytosisNot known
Immune system disorder
Drug hypersensitivity Uncommon
Anaphylactic reaction Rare
Angioedema Rare
Urticaria Rare
Rash Rare
Pruritus Rare
Bronchospasm Not known
Nervous system disorders
Intracranial haemorrhage Rare
Vascular disorders
Haematoma Uncommon
Wound haemorrhageUncommon
HaemorrhageRare
Respiratory, thoracic and mediastinal disorders
EpistaxisUncommon
Haemoptysis Rare
Gastrointestinal disorders
Gastrointestinal haemorrhageUncommon
Rectal haemorrhage Uncommon
Haemorrhoidal haemorrhageUncommon
DiarrhoeaUncommon
NauseaUncommon
Vomiting Uncommon
Gastrointestinal ulcer, including oesophageal
ulcer
Rare
Gastroesophagitis Rare
Gastroesophageal reflux disease Rare
Abdominal pain Rare
DyspepsiaRare
DysphagiaRare
Hepatobiliary disorders
Hepatic function abnormal/ Liver function Test
abnormal
Common
Alanine aminotransferase increased Uncommon
Aspartate aminotransferase increased Uncommon
Hepatic enzyme increasedUncommon
HyperbilirubinaemiaUncommon
Skin and subcutaneous tissue disorder
Skin haemorrhage Uncommon
Alopecia Not known
Musculoskeletal and connective tissue disorders
HaemarthrosisUncommon
Renal and urinary disorders
Genitourological haemorrhage, including
haematuria
Uncommon
General disorders and administration site conditions
Injection site haemorrhageRare
Catheter site haemorrhageRare
Bloody discharge Rare
Injury, poisoning and procedural complications
Traumatic haemorrhage Uncommon
Post procedural haematoma Uncommon
Post procedural haemorrhage Uncommon
Post procedural discharge Uncommon
Wound secretion Uncommon
Incision site haemorrhage Rare
Anaemia postoperative Rare
Surgical and medical procedures
Wound drainageRare
Post procedural drainage Rare

Description of selected adverse reactions

Bleeding reactions

Due to the pharmacological mode of action, the use of dabigatran etexilate may be associated with an increased risk of occult or overt bleeding from any tissue or organ. The signs, symptoms, and severity (including fatal outcome) will vary according to the location and degree or extent of the bleeding and/or anaemia. In the clinical studies mucosal bleedings (e.g. gastrointestinal, genitourinary) were seen more frequently during long term dabigatran etexilate treatment compared with VKA treatment. Thus, in addition to adequate clinical surveillance, laboratory testing of haemoglobin/haematocrit is of value to detect occult bleeding. The risk of bleedings may be increased in certain patient groups e.g. those patients with moderate renal impairment and/or on concomitant treatment affecting haemostasis or strong P-gp inhibitors (see section 4.4 Haemorrhagic risk). Haemorrhagic complications may present as weakness, paleness, dizziness, headache or unexplained swelling, dyspnoea, and unexplained shock.

Known bleeding complications such as compartment syndrome and acute renal failure due to hypoperfusion and anticoagulant-related nephropathy in patients with predisposing risk factors have been reported for dabigatran etexilate. Therefore, the possibility of haemorrhage is to be considered in evaluating the condition in any anticoagulated patient. For adult patients, a specific reversal agent for dabigatran, idarucizumab, is available in case of uncontrollable bleeding (see Section 4.9).

The table 11 shows the number (%) of patients experiencing the adverse reaction bleeding during the treatment period in the indication primary VTE prevention after hip or knee replacement surgery in the two pivotal clinical trials, according to dose.

Table 11. Number (%) of patients experiencing the adverse reaction bleeding:

 Dabigatran etexilate
150 mg
N (%)
Dabigatran etexilate
220 mg
N (%)
Enoxaparin

N (%)
Treated 1,866 (100.0) 1,825 (100.0) 1,848 (100.0)
Major bleeding 24 (1.3) 33 (1.8) 27 (1.5)
Any bleeding 258 (13.8) 251 (13.8) 247 (13.4)

Agranulocytosis and neutropenia

Agranulocytosis and neutropenia have been reported very rarely during post approval use of dabigatran etexilate. Because adverse reactions are reported in the postmarketing surveillance setting from a population of uncertain size, it is not possible to reliably determine their frequency. The reporting rate was estimated as 7 events per 1 million patient years for agranulocytosis and as 5 events per 1 million patient years for neutropenia.

Paediatric population

The safety of dabigatran etexilate in the treatment of VTE and prevention of recurrent VTE in paediatric patients was studied in two phase III trials (DIVERSITY and 1160.108). In total, 328 paediatric patients had been treated with dabigatran etexilate. The patients received age and weight adjusted doses of an age-appropriate formulation of dabigatran etexilate.

Overall, the safety profile in children is expected to be the same as in adults.

In total, 26% of paediatric patients treated with dabigatran etexilate for VTE and for prevention of recurrent VTE experienced adverse reactions.

Tabulated list of adverse reactions

Table 12 shows the adverse reactions identified from the studies in the treatment of VTE and prevention of recurrent VTE in paediatric patients. They are ranked under headings of System Organ Class (SOC) and frequency using the following convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).

Table 12. Adverse reactions:

 Frequency
SOC / Preferred term. treatment of VTE and prevention of recurrent VTE in
paediatric patients
Blood and lymphatic system disorders
Anaemia Common
Haemoglobin decreased Uncommon
Thrombocytopenia Common
Haematocrit decreasedUncommon
Neutropenia Uncommon
Agranulocytosis Not known
Immune system disorder
Drug hypersensitivity Uncommon
Rash Common
PruritusUncommon
Anaphylactic reaction Not known
Angioedema Not known
Urticaria Common
Bronchospasm Not known
Nervous system disorders
Intracranial haemorrhage Uncommon
Vascular disorders
Haematoma Common
HaemorrhageNot known
Respiratory, thoracic and mediastinal disorders
EpistaxisCommon
Haemoptysis Uncommon
Gastrointestinal disorders
Gastrointestinal haemorrhageUncommon
Abdominal pain Uncommon
Diarrhoea Common
Dyspepsia Common
Nausea Common
Rectal haemorrhage Uncommon
Haemorrhoidal haemorrhage Not known
Gastrointestinal ulcer, including
oesophageal ulcer
Not known
Gastroesophagitis Uncommon
Gastroesophageal reflux disease Common
Vomiting Common
Dysphagia Uncommon
Hepatobiliary disorders
Hepatic function abnormal/Liver
function Test abnormal
Not known
Alanine aminotransferase increased Uncommon
Aspartate aminotransferase increased Uncommon
Hepatic enzyme increased Common
Hyperbilirubinaemia Uncommon
Skin and subcutaneous tissue disorder
Skin haemorrhage Uncommon
Alopecia Common
Musculoskeletal and connective tissue disorders
Haemarthrosis Not known
Renal and urinary disorders
Genitourological haemorrhage,
including haematuria
Uncommon
General disorders and administration site conditions
Injection site haemorrhage Not known
Catheter site haemorrhage Not known
Injury, poisoning and procedural complications
Traumatic haemorrhage Uncommon
Incision site haemorrhage Not known

Bleeding reactions

In the two phase III trials in the indication treatment of VTE and prevention of recurrent VTE in paediatric patients, a total of 7 patients (2.1%) had a major bleeding event, 5 patients (1.5%) a clinically relevant non-major bleeding event and 75 patients (22.9%) a minor bleeding event. The frequency of bleeding events was overall higher in the oldest age group (12 to <18 years: 28.6%) than in the younger age groups (birth to <2 years: 23.3%; 2 to <12 years: 16.2%). Major or severe bleeding, regardless of location, may lead to disabling, life-threatening or even fatal outcomes.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

Incompatibilities

Not applicable.

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.